Abstract

Hazard evaluation of engineered nanomaterials (ENMs) using real-world exposure scenario could provide better interpretation of toxicity end points for their use in the assessment of human safety and for their implications in many fields such as toxicology, nanomedicine, and so forth. However, most of the current studies, both in vivo and in vitro, do not reflect realistic conditions of human exposure to ENMs, due to the high doses implemented. Moreover, the use of cellular models cultured under submerged conditions limits their physiological relevance for lung exposure, where cells are primarily cultured at the air-liquid interface. Addressing such issues is even more challenging for emergent nanomaterials, such as graphene oxide (GO), for which little or no information on exposure is available. In this work, we studied the impact of repeated exposure of GO on a three-dimensional (3D) reconstruct of human bronchial tissue, using a nebulizer system focusing on short-term effects. The selected doses (reaching a maximum of ca. 20 ​μg/cm2 for a period of 4 weeks of exposure) were extrapolated from alveolar mass deposition values of a broader class of carbon-based nanomaterials, reflecting a full working lifetime of human exposure. Experimental results did not show strong toxic effects of GO in terms of viability and integrity of the lung tissue. However, since 2 weeks of treatment, repeated GO exposure elicited a proinflammatory response, moderate barrier impairment, and autophagosome accumulation, a process resulting from blockade of autophagy flux. Interestingly, the 3D airway model could recover such an effect by restoring autophagy flux at longer exposure (30 days). These findings indicate that prolonged exposure to GO produces a time window (during the 30 days of treatment set for this study) for which GO-mediated autophagy inhibition along with inflammation may potentially increase the susceptibility of exposed humans to pulmonary infections and/or lung diseases. This study also highlights the importance of using physiologically relevant in vitro models and doses derived from real-world exposure to obtain focused data for the assessment of human safety.

Highlights

  • Worldwide efforts of nanosafety community are devoted to produce toxicity-oriented data to inform stakeholders (Regulatory Bodies/Policy Institutions) on the exposure limits and potential hazard effects of emergent technologies based on nanomaterials, including graphene family materials (GFMs) [1]

  • By means of a nebulizer system, using doses (0.7–20 μg/cm2), which reflect a real worker exposure lifetime to graphene oxide (GO) in a production facility, a 3D airway model was repeatedly exposed to GO for 4 weeks, and the effects exerted were followed at short term

  • Experimental data indicated that, at the conditions used in this study, 30day repeated exposure to GO did not elicit strong toxic effects at short term, as opposite to a 2D cell system, based on BEAS-2B bronchial cell line

Read more

Summary

Introduction

Worldwide efforts of nanosafety community are devoted to produce toxicity-oriented data to inform stakeholders (Regulatory Bodies/Policy Institutions) on the exposure limits and potential hazard effects of emergent technologies based on nanomaterials, including graphene family materials (GFMs) [1]. Based on these observations, the evaluation of the potential toxicity of graphene nanoforms appears urgent, as human exposure may occur (occupational, nanomedicine, consumers) [6,7,8]. Considering the worker exposure (that could occur repeatedly over the entire timeframe of the working lifetime, usually estimated in the range of 30–40 years), the need for inhalation studies which could take into account a cumulative response appears clear (prolonged repeated exposure) [7]. It is worth mentioning the in vitro study of Drasler at al. By analyzing the current scenario, it seems that no clear relationship between the generated toxicity data and human occupational exposure can be possible so far; no regulatory limits can be extrapolated

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.